Valneva (NASDAQ:VALN) Sees Large Volume Increase

Shares of Valneva SE (NASDAQ:VALN) saw strong trading volume on Thursday . 14,333 shares traded hands during trading, an increase of 34% from the previous session’s volume of 10,711 shares.The stock last traded at $7.37 and had previously closed at $7.57.

Analysts Set New Price Targets

Several equities research analysts have issued reports on the stock. HC Wainwright reiterated a “buy” rating and set a $26.00 target price on shares of Valneva in a research report on Thursday, March 21st. Guggenheim decreased their price target on shares of Valneva from $18.00 to $17.00 and set a “buy” rating on the stock in a research note on Friday, March 22nd.

Valneva Price Performance

The stock has a market capitalization of $536.92 million, a PE ratio of -4.88 and a beta of 2.22. The firm’s 50 day simple moving average is $7.67 and its 200 day simple moving average is $9.36. The company has a debt-to-equity ratio of 1.04, a current ratio of 1.65 and a quick ratio of 1.37.

Valneva (NASDAQ:VALN) last posted its quarterly earnings results on Wednesday, March 20th. The company reported ($0.50) EPS for the quarter, missing the consensus estimate of $0.20 by ($0.70). Valneva had a negative return on equity of 59.48% and a negative net margin of 65.99%. The business had revenue of $45.12 million for the quarter, compared to analysts’ expectations of $45.06 million. As a group, equities analysts forecast that Valneva SE will post 0.11 EPS for the current fiscal year.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Valneva stock. General American Investors Co. Inc. raised its stake in shares of Valneva SE (NASDAQ:VALN) by 2.7% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 354,361 shares of the company’s stock after purchasing an additional 9,361 shares during the quarter. General American Investors Co. Inc. owned approximately 0.51% of Valneva worth $2,831,000 at the end of the most recent reporting period. Institutional investors own 11.39% of the company’s stock.

Valneva Company Profile

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.